[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638039":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":28,"responsibleParty":45,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":71,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Medical University Innsbruck","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"STEMI Patients",null,"Patients presenting with ST-elevation myocardial infarction (STEMI) who undergo successful primary percutaneous coronary intervention (PCI). All consecutive eligible patients are enrolled regardless of CHIP mutation status. This single cohort is analyzed based on CHIP presence\u002Fabsence and specific CHIP mutation type (e.g., DNMT3A, TET2, ASXL1).",[13],"Diagnostic Test: Clonal hematopoiesis assessment and cardiac magnetic resonance imaging",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Clonal hematopoiesis assessment and cardiac magnetic resonance imaging","Participants will undergo blood sampling for assessment of clonal hematopoiesis of indeterminate potential by targeted next-generation sequencing and cardiac magnetic resonance imaging for assessment of myocardial injury, including microvascular obstruction, intramyocardial hemorrhage, infarct size, ventricular function, and myocardial tissue characteristics. Additional biomarker and inflammatory profiling will be performed according to the study protocol.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Ivan Lechner, MD, PhD","CONTACT","+43 512 504 83772","ivan.lechner@tirol-kliniken.at",{"name":27,"role":23,"phone":24,"phoneExt":10,"email":10},"Sebastian J Reinstadler, MD, PhD",[29],{"facility":30,"status":10,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Medical University of Innsbruck","Innsbruck","Tyrol","6020","Austria","AT",{"type":37,"coordinates":38},"Point",[39,40],11.39454,47.26266,{"lat":40,"lon":39},[43,44],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"name":27,"role":23,"phone":24,"phoneExt":10,"email":10},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100638039","clonal-hematopoiesis-of-indeterminate-potential-and-infarct-severity-in-st-elevation-myocardial-infarction-100638039",false,"NCT07615023","Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction","CHIP in STEMI","Inclusion Criteria:\n\n* Diagnosis of first acute ST-elevation myocardial infarction according to current European Society of Cardiology guidelines\n* Symptoms consistent with ST-elevation myocardial infarction lasting more than 30 minutes and less than 12 hours before primary percutaneous coronary intervention\n* Treatment with primary percutaneous coronary intervention\n* Age 18 to 75 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Prior myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention\n* Persistent hemodynamic instability, Killip class greater than 2 including cardiogenic shock, or resuscitated cardiac arrest not allowing cardiac magnetic resonance imaging\n* Known active or prior malignancy, including hematologic malignancies or myelodysplastic syndromes\n* Prior oncologic treatment with chemotherapy, radiotherapy, or radioisotopes\n* Abnormal baseline complete blood count with clinically significant cytopenia, defined as leukocytes less than 3.0 x 10\\^9\u002FL, platelets less than 100 x 10\\^9\u002FL, or hemoglobin less than 10 g\u002FdL\n* Chronic viral infection associated with systemic inflammation\n* Active autoimmune disease or chronic systemic inflammatory disorder\n* Chronic kidney disease with creatinine clearance less than 30 mL\u002Fmin\u002F1.73 m2\n* Contraindication to cardiac magnetic resonance imaging\n* Pre-ST-elevation myocardial infarction life expectancy of less than 1 year\n* Participation in an interventional trial\n* Limited possibility to attend follow-up examinations, for example residence abroad\n* Pregnancy",true,"ALL","18 Years","75 Years",{"count":59,"type":60},350,"ESTIMATED","OBSERVATIONAL","Clonal Hematopoiesis of Indeterminate Potential (CHIP) refers to the age-related expansion of hematopoietic stem cell clones carrying somatic mutations in leukemia-associated driver genes (e.g., DNMT3A, TET2, ASXL1) in the absence of a hematological malignancy. CHIP has been identified as an independent cardiovascular risk factor associated with increased rates of myocardial infarction, stroke, and cardiovascular mortality, likely mediated through enhanced inflammatory signaling in mutant macrophages and monocytes.\n\nST-elevation myocardial infarction (STEMI) is a life-threatening emergency requiring immediate reperfusion by primary percutaneous coronary intervention (PCI). Despite successful reperfusion, adverse cardiac remodeling and heart failure may occur depending on myocardial injury severity, microvascular obstruction (MVO), and intramyocardial hemorrhage (IMH) - phenomena substantially driven by ischemia-reperfusion injury and the inflammatory response.\n\nThe CHIP in STEMI study is a prospective, observational, single-center cohort study at the Medical University of Innsbruck investigating whether CHIP - detected by targeted next-generation sequencing - is associated with greater infarct severity and worse cardiac outcomes in STEMI patients undergoing primary PCI. The primary endpoint is the presence of MVO and\u002For IMH on cardiac MRI (CMR) at 5±2 days post-PCI. Secondary endpoints include infarct size, left and right ventricular function, major adverse cardiovascular events (MACE), and immune cell transcriptome profiling by single-cell RNA sequencing.\n\n350 patients (18-75 years, minimum 90 female) will be enrolled over 36 months and followed for 4 years (2026-2030).",[64,65],"ST-elevation Myocardial Infarction (STEMI)","Clonal Hematopoiesis of Indeterminate Potential (CHIP)",[67,68,69,70],"CHIP","STEMI","cardiac MRI","microvascular obstruction","NOT_YET_RECRUITING","2026-05-22",{"date":74,"type":75},"2026-05-29","ACTUAL",{"date":77,"type":60},"2026-06-20",{"date":79,"type":60},"2030-06-20",{"name":5,"class":6},1]